Pharmaceutical-grade urea supplied as a GMP-compliant API with a Type II drug master file under 21 CFR 314.420 is used in immediate-release oral tablet formulations where the active load must be delivered with acceptable content uniformity despite high aqueous solubility and hygroscopicity. If the designation DMF is considered as residual N,N-dimethylformamide rather than the Drug Master File, the solvent is controlled under ICH Q3C Class 2 at a concentration limit of 880 ppm and a permitted daily exposure of 8.8 mg/day, aligned to USP <467>. Direct compression on a rotary tablet press at main compression forces between 10 kN and 18 kN uses 10.5 mm round flat-faced beveled tooling and produces tablets with friability below 1.0% when tested under USP <1216>. Urea crystals exhibit brittle fracture rather than plastic deformation; at loads above 60% (w/w), capping and lamination may occur on production batches when the particle-size distribution D90 exceeds 150 µm or when blend moisture content exceeds 0.5%. Because urea sorbs moisture above 45% RH, processing suites without humidity control require pre-drying at or below 60% RH for direct compression. Microcrystalline cellulose PH-102 is the preferred filler, crospovidone at 2–5% is used as disintegrant, and magnesium stearate is limited to 1.0% or less to avoid hydrophobic film formation that increases disintegration time under USP <701> beyond the desired 15 min window. A flowability check under USP <1174> is performed because crystalline urea with an acicular habit may show angle of repose above 40°, requiring glidants such as colloidal silicon dioxide at 0.5–1.0%. Bulk tablet storage in HDPE bottles with heat-sealed foil liners is maintained below 25 °C and 40% RH; long-term stability is evaluated at 30 °C/65% RH and accelerated conditions at 40 °C/75% RH under ICH Q1A. Water content by Karl Fischer titration under USP <921> is limited to 0.5% for direct compression input material.

What Limits Capsule Fill Weight Uniformity in High-Dose Urea Capsules?

Capsule filling of high-dose urea formulations on an intermittent-motion dosator machine or a continuous rotary capsule filler is constrained by fill weight, powder flow, and moisture exchange between the fill and the shell. For size 00 hard capsules with fill weights above 600 mg, blend bulk density must be above 0.4 g/mL to permit reproducible plug formation; lower bulk density powders require pre-compaction or slugging to prevent weight variation failures under USP <905>. Because urea is highly water-soluble, dissolution testing under USP <711> in 900 mL water at 37 °C with paddle speed 50 rpm typically shows release above 80% within 30 min; however, the hydrophilic nature also creates a risk of moisture migration into the shell. Gelatin capsule shells stored above 60% RH may soften, while at low RH they may embrittle, and the hygroscopic urea fill can transfer moisture to the shell during prolonged storage. HPMC capsules are selected when storage conditions are not tightly controlled, and silica gel desiccant in the package is set to maintain headspace RH below 40%. For compounded capsules prepared under USP <795>, geometric dilution is required for lower-dose strengths, and the acceptance value under USP <905> is typically 15.0 or below for 10 units. Automated capsule filling controls dosator height and powder bed height to maintain plug density, and weight variation is monitored at 15 min intervals during filling. Urea-loaded capsules are not suitable for open storage in polyvinyl chloride blister cavities without additional barrier layers because PVC is moderately permeable to moisture and may allow caking of the fill.

When direct compression cannot deliver adequate tablet hardness without unacceptable friability, a top-spray fluid-bed granulation step is introduced to densify the urea-containing formulation and improve flowability. An aqueous binder of povidone K30 at 5% (w/w) solids is sprayed onto a fluidized blend of urea, lactose monohydrate, and crospovidone, with inlet air temperature between 60 °C and 70 °C and product temperature maintained between 30 °C and 35 °C. The spray rate is adjusted to keep the mass below the liquid saturation point because urea dissolves in the aqueous binder and can cause uncontrolled agglomeration; granulation end point is defined by loss on drying below 1.0% and granule D50 between 150 µm and 300 µm. The dried granules are milled through a 0.8 mm screen and lubricated with sodium stearyl fumarate rather than magnesium stearate in formulations where disintegration lag is a concern. Granule flow after drying is confirmed by angle of repose below 35° under USP <1174>. Tablets compressed from these granules at 12–16 kN show friability below 0.8% and disintegration below 10 min under USP <701>; the disintegration advantage over direct compression arises from the porous granule structure that allows water channel penetration around urea-rich regions. Residual moisture is equilibrated in a humidity-controlled dryer at 25 °C/40% RH before packaging to prevent surface dissolution of urea during storage. Overgranulation generates coarse granules above 800 µm that segregate in the tablet press hopper and increase weight variation; in-line particle-size monitoring is therefore placed after the mill to reject out-of-specification granule fractions.

When Terminal Sterilization Becomes the Injectable Urea Bottleneck

Injectable urea processing starts with a depyrogenated API with bioburden and bacterial endotoxin limits defined by USP <85>, USP <61>, and USP <62>, but terminal steam sterilization of the final aqueous solution is complicated by the thermal sensitivity of urea. Aqueous urea degrades through hydrolysis to ammonia, carbon dioxide, and biuret; autoclave cycles at 121 °C for 15 min may increase biuret and pH beyond the specified release range. For this reason, aseptic filtration through 0.22 µm PVDF membrane filters in an ISO 14644-1 Class 5 environment is used for heat-labile urea solutions, with filter integrity testing performed before and after filtration. If a terminal sterilization cycle is selected, the hold time at 121 °C must be limited and solution pH is adjusted to 6.0–7.5 to minimize hydrolysis; published data for this specific configuration is limited, but rapid cooling from 80 °C to 25 °C in a jacketed stainless steel vessel limits ammonia formation. Filled vials are inspected for particulate matter under USP <788> and visible particles under USP <790>. The hyperosmolar nature of 30% (w/v) urea solution, with an osmolality above 5000 mOsm/kg, prohibits rapid peripheral intravenous administration and dictates infusion through a central venous line with volumetric pump control.

High-Dose Oral Granule Sachet Fill Weight and Reconstitution Osmolarity

Sachet filling of urea granules at fill weights from 1 g to 15 g is carried out on horizontal form-fill-seal lines with auger or volumetric fillers; fill weight uniformity is monitored under USP <905> and requires granule density above 0.4 g/mL and flow relative standard deviation below 15%. When the granule is reconstituted in 200 mL water, a 15 g urea dose produces a solution concentration of 75 g/L, corresponding to an osmolality near 1250 mOsm/kg, which is hyperosmotic relative to oral fluids. The dissolution of urea in water is endothermic, and the reconstituted solution temperature can fall below 10 °C; this cooling effect is a useful in-line control check for complete dissolution. Palatability modifiers are restricted to those compatible with urea in aqueous solution; citric acid buffers may lower pH and increase hydrolysis, so buffered formulations are tested for ammonia generation during shelf-life under ICH Q1A conditions. The sachet laminate must include aluminum foil because urea granules absorb moisture above 45% RH and may cake; desiccant is not placed inside the sachet because direct contact with urea granules can cause localized moisture transfer and hardening. Tube compatibility testing for dysphagia use includes 30 mL water flushes to prevent crystalline residue build-up in narrow-bore enteral tubes.

Across tablet, capsule, granule, and injectable lines, residual N,N-dimethylformamide is controlled as a Class 2 solvent under ICH Q3C when the synthetic route involves DMF as a crystallization or reaction solvent. The concentration limit of 880 ppm applies to all dosage forms unless a higher limit is justified by reduced daily intake, and gas chromatography with headspace sampling is performed according to USP <467> Option 1. For a Type II drug master file, the API manufacturer maintains open and closed portions under 21 CFR 314.420 and provides letters of authorization for dossier cross-reference. The GMP status of urea for oral solid dosage forms requires microbial enumeration under USP <61> and specified organisms under USP <62>; injectable urea adds sterility testing under USP <71>, bacterial endotoxin testing under USP <85>, and particulate matter testing under USP <788>. The compliance matrix below summarizes the primary pharmacopoeial control points by dosage form.

Thermal Degradation Pathways in Aqueous Urea Solutions

Aqueous urea undergoes pH-dependent hydrolysis that is slowest near neutral pH; in the pH range 6.0–7.5, ammonia formation is minimized, while acidic conditions below pH 4 and alkaline conditions above pH 8 accelerate conversion to ammonium carbamate and subsequently ammonia and carbon dioxide. The degradation sequence is relevant to injectable solutions and reconstituted oral granules because ammonia raises pH and contributes to the odor and irritation profile of the product. At high temperatures above 80 °C, urea may also form biuret and cyanuric acid derivatives in trace amounts, which are controlled by related substances testing in the API and drug product. For aqueous formulations, stainless steel and borosilicate glass are preferred contact materials; contact with certain copper alloys may catalyze decomposition. Solutions are protected from light and stored at controlled room temperature below 25 °C; headspace ammonia in accelerated stability studies is monitored at 40 °C/75% RH under ICH Q1A to detect degradation before release. Because urea is highly soluble, dissolution is not the rate-limiting quality attribute for injectable or reconstituted oral products; instead, pH shift and ammonia content are the practical markers of solution instability. Published data for this specific configuration is limited, but the general hydrolysis sensitivity is documented in pharmaceutical excipient monographs and urea solution handling guides.